Skip to main content
. 2017 Sep 1;8(45):79991–80001. doi: 10.18632/oncotarget.20620

Figure 3. Effects of IVIg on GBS.

Figure 3

A. In the mild GBS group, the GBS disability scale scores of IVIg-treated patients and supportive care-received patients at admission, nadir, discharge and 2-12 years after the acute phase were 2, 2, 1, 0, with IQR of 1-2, 1-3, 1-1.25, 0-1.25 and 2, 2, 1, 1, with IQR of 1-2, 1-2, 1-2, 0-2, respectively. IVIg-treated patients had a significantly higher GBS disability scale score at nadir. B. In the moderate/severe GBS group, the GBS disability scale scores, of patients who were treated with IVIg, at admission, nadir, discharge and 2-12 years after the acute phase were 3.5, 4, 2, 0, with IQR of 3-4, 3-4, 1-4, 0-1.25, and its counterparts of GBS patients who were received supportive care only were 4, 4, 3, 1, with IQR of 3-4, 3-4, 2-4, 0-2, respectively. Patients in supportive care group had a significantly higher GBS disability scale score both at admission and at nadir.